BR0307518A - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BR0307518A
BR0307518A BR0307518-4A BR0307518A BR0307518A BR 0307518 A BR0307518 A BR 0307518A BR 0307518 A BR0307518 A BR 0307518A BR 0307518 A BR0307518 A BR 0307518A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
relates
composition
propofol
producing
Prior art date
Application number
BR0307518-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence John Penkler
Original Assignee
Shimoda Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimoda Biotech Pty Ltd filed Critical Shimoda Biotech Pty Ltd
Publication of BR0307518A publication Critical patent/BR0307518A/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0307518-4A 2002-02-01 2003-01-29 Composição farmacêutica BR0307518A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA200200929 2002-02-01
US40163302P 2002-08-06 2002-08-06
PCT/IB2003/000266 WO2003063824A2 (en) 2002-02-01 2003-01-29 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR0307518A true BR0307518A (pt) 2004-12-28

Family

ID=27669352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307518-4A BR0307518A (pt) 2002-02-01 2003-01-29 Composição farmacêutica

Country Status (12)

Country Link
US (1) US20050239746A1 (enExample)
EP (1) EP1469886B8 (enExample)
JP (1) JP2005522422A (enExample)
CN (1) CN1625414A (enExample)
AT (1) ATE326985T1 (enExample)
AU (1) AU2003205930B2 (enExample)
BR (1) BR0307518A (enExample)
CA (1) CA2474710A1 (enExample)
DE (1) DE60305438T2 (enExample)
MX (1) MXPA04007328A (enExample)
NZ (1) NZ534598A (enExample)
WO (1) WO2003063824A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1574221T3 (da) * 2004-03-10 2007-07-16 Shimoda Biotech Pty Ltd Stabile, injicérbare diclofenacsammensætninger
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
JPWO2006112276A1 (ja) 2005-04-13 2008-12-11 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
JP2009504634A (ja) * 2005-08-12 2009-02-05 ブハラット セルムズ アンド ヴァクシンズ リミテッド プロポフォールを含む水性麻酔剤組成物
BRPI0709409A2 (pt) 2006-03-28 2011-07-12 Javelin Pharmaceuticals Inc composição farmacêutica e método para tratar um mamìfero necessitando de analgesia
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
EP2484350B1 (de) * 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin
SG11201401597TA (en) 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
CN103172658B (zh) * 2011-12-26 2016-01-20 宜昌人福药业有限责任公司 一种适合药用的前体药物晶型、制备方法及药用组合物
CN104870001B (zh) 2012-11-15 2019-01-18 赛博尔泰克股份公司 用作消炎或免疫抑制有效成分的飞燕草素络合物
HK1215392A1 (zh) 2012-12-11 2016-08-26 赛博尔泰克股份公司 用於对抗黑色素瘤细胞的飞燕草素
EP2913050A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
CN104523591B (zh) * 2014-12-19 2019-01-18 西安力邦肇新生物科技有限公司 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法
CN111529695A (zh) * 2020-04-30 2020-08-14 首都医科大学附属北京康复医院(北京工人疗养院) 一种环糊精可溶性ace2及其制备方法和应用
KR20220057901A (ko) * 2020-10-30 2022-05-09 현대자동차주식회사 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
WO2023156970A1 (en) * 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
NZ331509A (en) * 1996-02-19 2000-04-28 Nycomed Imaging As Aqueous dispersions of stabilised gas microbubbles and their use as contrast agents
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
EP1244444B1 (en) * 1999-10-29 2004-12-29 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
IN187686B (enExample) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
US20050239746A1 (en) 2005-10-27
ATE326985T1 (de) 2006-06-15
CA2474710A1 (en) 2003-08-07
AU2003205930B2 (en) 2007-08-16
DE60305438D1 (de) 2006-06-29
EP1469886B1 (en) 2006-05-24
WO2003063824A2 (en) 2003-08-07
DE60305438T2 (de) 2006-12-21
NZ534598A (en) 2004-11-26
EP1469886B8 (en) 2008-01-09
EP1469886A2 (en) 2004-10-27
WO2003063824A3 (en) 2004-06-17
MXPA04007328A (es) 2005-07-05
CN1625414A (zh) 2005-06-08
JP2005522422A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
BR0307518A (pt) Composição farmacêutica
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
ATE250431T1 (de) Verbesserte zusammensetzungen mit unkomplexiertem cyclodextrin zur geruchskontrolle
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
WO2006012527A8 (en) Bivalent linkers and conjugates thereof
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EA200200313A1 (ru) Применение доцетаксела для лечения печеночно-клеточного рака
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
ATE485261T1 (de) Salicylsäurederivate
SE0300457D0 (sv) Novel compounds
BRPI0417205A (pt) composições farmacêuticas
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
DK1503803T3 (da) Injicerbar farmaceutisk sammensætning indeholdende ethanol til at behandle diskusprolaps
EA200701688A1 (ru) Замещённые пирролы, содержащие их композиции, способ получения и применение

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 47/69 (2017.01)